Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inosine in Amyotrophic Lateral Sclerosis
NCT02288091Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of inosine in amyotrophic lateral sclerosis (ALS), sponsored by Massachusetts General Hospital. Primary endpoint: Number of Participants Experiencing Adverse Events at 12 weeks. Started Jan 2015; status: completed.
02
Drugs
inosine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02288091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02288091.